ID: ALA301138

Max Phase: Preclinical

Molecular Formula: C21H14N2O3

Molecular Weight: 342.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccccc21

Standard InChI:  InChI=1S/C21H14N2O3/c1-23-10-14(12-6-2-4-8-16(12)23)18-19(21(25)22-20(18)24)15-11-26-17-9-5-3-7-13(15)17/h2-11H,1H3,(H,22,24,25)

Standard InChI Key:  KCBBKYDLIADLOS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 342.35

Molecular Weight (Monoisotopic): 342.1004

AlogP: 3.49

#Rotatable Bonds: 2

Polar Surface Area: 64.24

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.71

CX Basic pKa:

CX LogP: 3.18

CX LogD: 3.18

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.57

Np Likeness Score: -0.09

References

1. Davis PD, Hill CH, Lawton G, Nixon JS, Wilkinson SE, Hurst SA, Keech E, Turner SE..  (1992)  Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.,  35  (1): [PMID:1732526] [10.1021/jm00079a024]

2. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD, Kozikowski AP..  (2009)  From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.,  52  (7): [PMID:19338355] [10.1021/jm801317h]

3. Wei J, Wang J, Zhang J, Yang J, Wang G, Wang Y..  (2022)  Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.,  236  [PMID:35390715] [10.1016/j.ejmech.2022.114301]

Source

Source(1):

• Scientific Literature